Fetal injection of antibodies against the c-Kit receptor and CD47 effectively depletes host HSCs in immunocompetent mice.• In utero depletion of host HSCs increases long-term engraftment after neonatal hematopoietic cell transplantation.Recently, simultaneous treatment with an anti-CD47 antibody was shown to potentiate the effect of ACK2 and result in much higher chimerism levels than seen in mice that received ACK2 alone. 20 CD47 is expressed on HSCs and acts as a "don't eat me" signal, preventing phagocytosis by macrophages and neutrophils via interaction with SIRPa. 21,22 Blockade of the CD47-SIRPa interaction enhances antibody-dependent depletion, allowing the combination strategy to achieve depletion, even in wild-type mice. Here, we explore the safety and efficacy of this combination strategy in fetal mice.
Methods MiceWild-type C57BL/6J (C57; CD45.2) and B6.SJL-PtrcaPep3b/BoyJ (BoyJ; CD45.1) mice were obtained from the National Cancer Institute. All mice were bred and maintained at the University of California, San Francisco. All procedures were performed according to the protocol approved by the University of California, San Francisco Institutional Animal Care and Use Committee.
In utero ACK2/MIAP410 injectionsPregnant dams were anesthetized at embryonic day 14.5 (E14.5) using isoflurane. A midline laparotomy was made, and the uterus was exteriorized. Fetal mice were injected with 2.5 mg of ACK2 or 2.5-mg concentrations of ACK2 and varying doses of MIAP410 (2.5 and 5 mg), or Dulbecco's phosphate buffered saline (PBS) as controls, in a volume of 5 mL per fetus at E14.5. ACK2 antibody was purchased from BioLegend (San Diego, CA). MIAP410 was purchased from Bio X Cell (West Lebanon, NH).
Neonatal transplantationNeonates were transplanted with congenic (B6.CD45.1/CD45.2) fetal liver mononuclear cells (FLMCs) on postnatal day 0 (P0) or P1. FLMCs were isolated from E13.5 or E14.5 donor fetuses by density